Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 196249, 9 pages
http://dx.doi.org/10.1155/2014/196249
Research Article

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts

Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222 Bialystok, Poland

Received 26 April 2013; Revised 5 November 2013; Accepted 23 November 2013; Published 29 January 2014

Academic Editor: Michael Kalafatis

Copyright © 2014 Rafał Krętowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. D. Zhang, P. Hersey, K. H. Tay, H. Y. Tseng, C. C. Jiang, and L. Dong, “Adaptation to ER stress as a mechanism of resistance of melanoma to treatment,” in Current Management of Malignant Melanoma, M. Y. Cao, Ed., InTech, Rijeka, Croatia, 2011. View at Google Scholar
  2. M. Kusaczuk and M. Cechowska-Pasko, “Molecular chaperone ORP150 in ER stress-related diseases,” Current Pharmaceutical Design, vol. 19, no. 15, pp. 2807–2818, 2013. View at Publisher · View at Google Scholar
  3. M. Tamatani, T. Matsuyama, A. Yamaguchi et al., “ORP150 protects against hypoxia/ischemia-induced neuronal death,” Nature Medicine, vol. 7, no. 3, pp. 317–323, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Ma and L. M. Hendershot, “The unfolding tale of the unfolded protein response,” Cell, vol. 107, no. 7, pp. 827–830, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. H. P. Harding, M. Calfon, F. Urano, I. Novoa, and D. Ron, “Transcriptional and translational control in the mammalian unfolded protein response,” Annual Review of Cell and Developmental Biology, vol. 18, pp. 575–599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. R. J. Kaufman, D. Scheuner, M. Schröder et al., “The unfolded protein response in nutrient sensing and differentiation,” Nature Reviews Molecular Cell Biology, vol. 3, no. 6, pp. 411–421, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Yoshida, “ER stress and diseases,” FEBS Journal, vol. 274, no. 3, pp. 630–658, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. L. J. Crawford and A. E. Irvine, “Proteasome inhibitors in the treatment of multiple myeloma,” in Multiple Myeloma-An Overview, A. Gupta, Ed., InTech, Rijeka, Croatia, 2012. View at Google Scholar
  9. A. M. Ruschak, M. Slassi, L. E. Kay, and A. D. Schimmer, “Novel proteasome inhibitors to overcome bortezomib resistance,” Journal of the National Cancer Institute, vol. 103, no. 13, pp. 1007–1017, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Frankland-Searby and S. R. Bhaumik, “The 26 S proteasome complex: an attractive target for cancer therapy,” Biochimica et Biophysica Acta, vol. 1825, no. 1, pp. 64–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Fribley and C. Wang, “Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress,” Cancer Biology and Therapy, vol. 5, no. 7, pp. 745–748, 2006. View at Google Scholar · View at Scopus
  12. Y. H. Han, S. Z. Kim, S. H. Kim, and W. H. Park, “Reactive oxygen species and glutathione level changes by a proteasome inhibitor, MG132, partially affect calf pulmonary arterial endothelial cell death,” Drug and Chemical Toxicology, vol. 33, no. 4, pp. 403–409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. H. Han and W. H. Park, “The changes of reactive oxygen species and glutathione by MG132, a proteasome inhibitor affect As4.1 juxtaglomerular cell growth and death,” Chemico-Biological Interactions, vol. 184, no. 3, pp. 319–327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Milani, T. Rzymski, H. R. Mellor et al., “The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib,” Cancer Research, vol. 69, no. 10, pp. 4415–4423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. B. Jänen, H. Chaachouay, and C. Richter-Landsberg, “Autophagy is activated by proteasomal inhibition and involved in aggresome clearance in cultured astrocytes,” GLIA, vol. 58, no. 14, pp. 1766–1774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. W. X. Ding, H. M. Ni, W. Gao et al., “Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability,” American Journal of Pathology, vol. 171, no. 2, pp. 513–524, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Sherman and G. Multhoff, “Heat shock proteins in cancer,” Annals of the New York Academy of Sciences, vol. 1113, pp. 192–201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Saretzki, “Cellular senescence in the development and treatment of cancer,” Current Pharmaceutical Design, vol. 16, no. 1, pp. 79–100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. D. Chang, E. V. Broude, M. Dokmanovic et al., “A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents,” Cancer Research, vol. 59, no. 15, pp. 3761–3767, 1999. View at Google Scholar · View at Scopus
  20. B. D. Chang, Y. Xuan, E. V. Broude et al., “Role of p53 and p21(waf1/cip1) in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs,” Oncogene, vol. 18, no. 34, pp. 4808–4818, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Collado, M. A. Blasco, and M. Serrano, “Cellular senescence in cancer and aging,” Cell, vol. 130, no. 2, pp. 223–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. P. Dimri, “What has senescence got to do with cancer?” Cancer Cell, vol. 7, no. 6, pp. 505–512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Palaniyappan, “Cyclophosphamide induces premature senescence in normal human fibroblasts by activating MAP kinases,” Biogerontology, vol. 10, no. 6, pp. 677–682, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. I. B. Roninson, “Tumor cell senescence in cancer treatment,” Cancer Research, vol. 63, no. 11, pp. 2705–2715, 2003. View at Google Scholar · View at Scopus
  25. C. Sõti, A. S. Sreedhar, and P. Csermely, “Apoptosis, necrosis and cellular senescence: chaperone occupancy as a potential switch,” Aging Cell, vol. 2, no. 1, pp. 39–45, 2003. View at Google Scholar · View at Scopus
  26. J. Carmichael, W. G. DeGraff, and A. F. Gazdar, “Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing,” Cancer Research, vol. 47, no. 4, pp. 936–942, 1987. View at Google Scholar · View at Scopus
  27. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  28. P. K. Smith, R. I. Krohn, and G. T. Hermanson, “Measurement of protein using bicinchoninic acid,” Analytical Biochemistry, vol. 150, no. 1, pp. 76–85, 1985. View at Google Scholar · View at Scopus
  29. T. A. Luster, J. A. Carrell, K. McCormick, D. Sun, and R. Humphreys, “Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib,” Molecular Cancer Therapeutics, vol. 8, no. 2, pp. 292–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr., K. P. Lee, and L. H. Boise, “Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells,” Blood, vol. 107, no. 12, pp. 4907–4916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. T. Nawrocki, J. S. Carew, M. S. Pino et al., “Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis,” Cancer Research, vol. 65, no. 24, pp. 11658–11666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Fribley and C. Y. Wang, “Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress,” Cancer Biology and Therapy, vol. 5, no. 7, pp. 745–748, 2006. View at Google Scholar · View at Scopus
  33. F. Morgillo, E. D'Aiuto, T. Troiani et al., “Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors,” Lung Cancer, vol. 71, no. 3, pp. 283–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. Laussmann, E. Passante, H. Düssmann et al., “Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8,” Cell Death and Differentiation, vol. 18, no. 10, pp. 1584–1597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Brenner and T. W. Mak, “Mitochondrial cell death effectors,” Current Opinion in Cell Biology, vol. 21, no. 6, pp. 871–877, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Z. Qin, J. Ziffra, L. Stennett et al., “Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells,” Cancer Research, vol. 65, no. 14, pp. 6282–6293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Gomez-Bougie, S. Wuillème-Toumi, E. Ménoret et al., “Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma,” Cancer Research, vol. 67, no. 11, pp. 5418–5424, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Nikiforov, M. Riblett, W. Tang et al., “Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19488–19493, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. D. A. Fennell, A. Chacko, and L. Mutti, “BCL-2 family regulation by the 20 S proteasome inhibitor bortezomib,” Oncogene, vol. 27, no. 9, pp. 1189–1197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. D. D. Mosser and R. I. Morimoto, “Molecular chaperones and the stress of oncogenesis,” Oncogene, vol. 23, no. 16, pp. 2907–2918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. V. L. Gabai, J. A. Yaglom, T. Waldman, and M. Y. Sherman, “Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells,” Molecular and Cellular Biology, vol. 29, no. 2, pp. 559–569, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Cechowska-Pasko, E. Bańkowski, and P. Chene, “The effect of hypoxia on the expression of 150 kDa oxygen-regulated protein (ORP 150) in HeLa cells,” Cellular Physiology and Biochemistry, vol. 17, no. 1-2, pp. 89–96, 2006. View at Publisher · View at Google Scholar · View at Scopus